SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 463,200 shares, a growth of 27.1% from the June 15th total of 364,300 shares. Based on an average daily trading volume, of 1,340,000 […]
SAB Biotherapeutics Inc (NASDAQ: SABS) announced the presentation of safety and pharmacologic data from a GLP toxicology study for SAB-142, a fully human immunotherapeutic being developed for delaying the onset and progression of Type 1 Diabetes.
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) saw a large drop in short interest during the month of May. As of May 31st, there was short interest totalling 428,100 shares, a drop of 35.7% from the May 15th total of 665,400 shares. Based on an average trading volume of 1,320,000 shares, the days-to-cover ratio is […]
SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Rating) was the recipient of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 8,500 shares, a decrease of 50.0% from the May 15th total of 17,000 shares. Based on an average daily volume of 25,900 shares, the […]
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) saw a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 665,400 shares, a growth of 28.3% from the April 30th total of 518,600 shares. Approximately 1.9% of the company’s stock are sold short. Based on an average […]